DVA

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

Investors need to pay close attention to DVA stock based on the movements in the options market lately.

An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.

DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.

DaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.

DaVita NYSE: DVA reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access to newer dialysis technology designed to improve clearance of so-called middle molecules.